
|Videos|July 20, 2022
Urology Times 50 Innovations Series: LHRH analogues in prostate cancer
Author(s)Urology Times staff
“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.
Advertisement
As part of the Urology Times' 50th Anniversary Innovation Celebration, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists in prostate cancer. Crawford is a professor of urology at the University of California, San Diego.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Lymph Node Dissection Following Systemic Therapy in MIBC
2
NCCN recommends ctDNA-MRD testing to guide adjuvant treatment post-cystectomy
3
European Commission approves perioperative EV/pembrolizumab for cisplatin-ineligible MIBC
4
Mina Fam, MD, highlights significance of tebipenem pivoxil approval for cUTI
5



















































